Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).

Fabrice André, Komal Jhaveri, Sherene Loi et al.|Journal of Clinical Oncology|2022

Cited by 25